FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:714-717 August 12, 2004 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Topol, E. J. Related Article by Cannon, C. P. PubMed Citation

To the Editor: Cannon and colleagues (April 8 issue)¹ report the results of the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22) study of an intensive lipid-lowering statin regimen. In contrast to the conclusions of the Heart Protection Study Collaborative Group,² their call for aggressive lowering of low-density lipoprotein (LDL) cholesterol is not fully supported by their data. Considering the high-risk population in the study by Cannon et al., we expected a beneficial effect with more aggressive lipid lowering, irrespective of the baseline lipid level. Although subgroup analysis is a thorny area, Figure 5 . . . [Full Text of this Article]

This article has been cited by other articles:

• Parini, P., Gustafsson, U., Davis, M. A., Larsson, L., Einarsson, C., Wilson, M., Rudling, M., Tomoda, H., Omura, S., Sahlin, S., Angelin, B., Rudel, L. L., Eriksson, M. (2008). Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2. Arterioscler. Thromb. Vasc. Bio. 28: 1200-1206 [Abstract] [Full Text]